Abstract
High grade gliomas represent one of the most aggressive and treatment-resistant types of human cancer, with only 1–2 years median survival rate for patients with grade IV glioma. The treatment of glioblastoma is a considerable therapeutic challenge; combination therapy targeting multiple pathways is becoming a fast growing area of research. This review offers an up-to-date perspective of the literature about current molecular therapy targets in high grade glioma, that include angiogenic signals, tyrosine kinase receptors, nodal signaling proteins and cancer stem cells related approaches. Simultaneous identification of proteomic signatures could provide biomarker panels for diagnostic and personalized treatment of different subsets of glioblastoma. Personalized medicine is starting to gain importance in clinical care, already having recorded a series of successes in several types of cancer; nonetheless, in brain tumors it is still at an early stage.
Keywords: Antiangiogenic therapy, cancer stem cells, glioma, microRNA, personalized medicine, PI-3K.
Current Proteomics
Title:Anti-cancer Therapies in High Grade Gliomas
Volume: 10 Issue: 3
Author(s): Cristiana Pistol Tanase, Ana-Maria Enciu, Simona Mihai, Ana Iulia Neagu, Bogdan Calenic and Maria Linda Cruceru
Affiliation:
Keywords: Antiangiogenic therapy, cancer stem cells, glioma, microRNA, personalized medicine, PI-3K.
Abstract: High grade gliomas represent one of the most aggressive and treatment-resistant types of human cancer, with only 1–2 years median survival rate for patients with grade IV glioma. The treatment of glioblastoma is a considerable therapeutic challenge; combination therapy targeting multiple pathways is becoming a fast growing area of research. This review offers an up-to-date perspective of the literature about current molecular therapy targets in high grade glioma, that include angiogenic signals, tyrosine kinase receptors, nodal signaling proteins and cancer stem cells related approaches. Simultaneous identification of proteomic signatures could provide biomarker panels for diagnostic and personalized treatment of different subsets of glioblastoma. Personalized medicine is starting to gain importance in clinical care, already having recorded a series of successes in several types of cancer; nonetheless, in brain tumors it is still at an early stage.
Export Options
About this article
Cite this article as:
Tanase Pistol Cristiana, Enciu Ana-Maria, Mihai Simona, Neagu Iulia Ana, Calenic Bogdan and Cruceru Linda Maria, Anti-cancer Therapies in High Grade Gliomas, Current Proteomics 2013; 10 (3) . https://dx.doi.org/10.2174/1570164611310030007
DOI https://dx.doi.org/10.2174/1570164611310030007 |
Print ISSN 1570-1646 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6247 |
Call for Papers in Thematic Issues
Mass spectrometry data acquisition and analysis for proteomics
The Thematic Issue on "Mass spectrometry data acquisition and analysis for proteomics" aims to explore the latest advancements and challenges in the field of proteomics through the lens of mass spectrometry. Proteomics, the large-scale study of proteins and their functions, plays a crucial role in understanding various biological processes and ...read more
Peptides: State-of-Art and Commercialisation Hurdles
The Editors of the Current Proteomics (CP) journal are highly privileged to welcome scientists to submit their scientific research and review articles to be considered for publication in the upcoming thematic issue. The topics should cover various aspects of peptides in regard to their synthetic methodologies, formulation approaches, pharmacological challenges, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
α(N)-Heterocyclic Thiosemicarbazones: Iron Chelators that are Promising for Revival of Gallium in Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Editorial: Brain Imaging and Automatic Analysis in Neurological and Psychiatric Diseases – Part II
CNS & Neurological Disorders - Drug Targets A Review of Various Machine Learning Techniques for Brain Tumor Detection from MRI Images
Current Medical Imaging Hyperpolarized 13Carbon MR
Current Pharmaceutical Biotechnology Annexins as Neuroprotective Agents in the Central Nervous System
Current Medicinal Chemistry - Central Nervous System Agents The Smart Targeting of Nanoparticles
Current Pharmaceutical Design Recent Developments in Targeted Therapies of the RAF-MEK and PI3KAKT Pathways in Cancer Treatment
Current Cancer Therapy Reviews IAPs, their Antagonists and their Role in Neurological Disease and Cancer
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Current Developments in Targeted Drug Delivery Systems for Glioma
Current Pharmaceutical Design The Adenine Nucleotide Translocase 2, a Mitochondrial Target for Anticancer Biotherapy
Current Drug Targets Enzyme-responsive Nanoparticles for Anticancer Drug Delivery
Current Nanoscience Targeted Therapy Options for Treatment of Bone Metastases; Beyond Bisphosphonates
Current Pharmaceutical Design Polymer-Based Drug Delivery Devices for Neurological Disorders
CNS & Neurological Disorders - Drug Targets Differential Effects of Doxazosin on Renin-Angiotensin-System- Regulating Aminopeptidase Activities in Neuroblastoma and Glioma Tumoral Cells
CNS & Neurological Disorders - Drug Targets Integrated Differential Regulatory Analysis Reveals a Novel Prognostic 36-Gene Signature for Gastric Cancer in Asian Population
Combinatorial Chemistry & High Throughput Screening Focus on the Role of Glutamate in the Pathology of the Peripheral Nervous System
CNS & Neurological Disorders - Drug Targets Understanding Autophagy in Cell Death Control
Current Pharmaceutical Design Peptide Prodrugs for the Treatment of CNS Disorders: A Perspective for New Drugs
Current Medicinal Chemistry Green Chemistry Starting from 2H-Pyran-2-one Derivatives
Current Green Chemistry Isoprenylation of Intracellular Proteins as a New Target for the Therapy of Human Neoplasms: Preclinical and Clinical Implications
Current Drug Targets